We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Celyad Oncology (CYAD) NPV

Sell:€0.65 Buy:€0.67 Change: €0.026 (4.00%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€0.65
Buy:€0.67
Change: €0.026 (4.00%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:€0.65
Buy:€0.67
Change: €0.026 (4.00%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).

Contact details

Address:
Rue Andre Dumont 9
MONT-SAINT-GUIBERT
1435
Belgium
Telephone:
+32 (10) 394100
Website:
https://www.celyad.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CYAD
ISIN:
BE0974260896
Market cap:
€26.93 million
Shares in issue:
41.43 million
Sector:
Biotechnology
Exchange:
Euronext Brussels
Country:
Belgium
Currency:
Euro
Indices:
n/a

Key personnel

  • Hilde Windels
    Chairwoman of the Board
  • Matt Kane
    Chief Executive Officer
  • Philippe Nobels
    Chief Human Resource Officer - Representative of MC Consult SRL, Member of the Executive Management Committee
  • David Gilham
    Chief Scientific Officer, Member of the Executive Management Committee
  • Fredrik Lehmann
    Vice President Clinical Development and Medical Affairs - Representative of ImXense SRL, Member of the Executive Management Committee
  • Charles Morris
    Chief Medical Officer
  • Philippe Dechamps
    Chief Legal Officer, Corporate Secretary - Representative of NandaDevi SRL, Member of the Executive Management Committee
  • Stephen Rubino
    Chief Business Officer, Member of the Executive Management Committee

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.